Table 1.
Characteristics of patients and treatment.
| Chemotherapy + bevacizumab (n = 67) | Chemotherapy alone (n = 62) | |
|---|---|---|
| Age at diagnosis (years), median IQR) | 51 (45–60) | 56 (46–61) |
| Menopause, n (%) | 45 (67) | 38 (61) |
| Histology, n (%) | ||
| Squamous | 46 (69) | 51 (82) |
| Adenocarcinoma | 16 (24) | 7 (11) |
| Other | 5 (8) | 4 (6) |
| ECOG performance status, n (%)a | ||
| 0 | 38 (57) | 15 (25) |
| 1 | 24 (36) | 29 (48) |
| 2 | 5 (7) | 16 (27) |
| Body mass index (kg/m2), median (IQR)b | 24 (22–29) | 24 (22–27) |
| Previous treatment, n (%) | ||
| No therapy before | 10 (15) | 9 (15) |
| Surgery alone | 10 (15) | 1 (2) |
| Chemoradiotherapy | 31 (46) | 41 (66) |
| Surgery + radiotherapy ± chemotherapy | 16 (24) | 11 (18) |
| Duration of targeted treatment (months), median (IQR) | 4.3 (2.8–8.0) | 3.7 (2.0–5.5) |
| Number of cycles, median (IQR)c | 6 (5–11) | 6 (3–6) |
| Follow-up (months), median (IQR) | 14.5 (8.6–20.5) | 10.9 (3.9–26.4) |
IQR = interquartile range (range between the 25th and 75th percentiles). aECOG performance status was missing for 2/62 (3%) patients treated with chemotherapy alone. bBody mass index was missing for 1/67 (1%) patients treated with bevacizumab and for 5/62 (8%) patients treated with chemotherapy alone. cNumber of cycles was missing for 3/62 (5%) patients treated with chemotherapy alone.